Cara Therapeutics Inc

Latest Cara Therapeutics Inc News and Updates

  • uploads///herb _
    Company & Industry Overviews

    Curaleaf Opens Medical Marijuana Dispensary in Tallahassee

    On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.

    By Mike Benson
  • uploads///cannabis _
    Company & Industry Overviews

    Cannabis Stocks Had a Mixed Performance Last Week

    Cannabis ETFs traded on a largely negative note last week.

    By Mohit Oberoi, CFA
  • uploads///part
    Company & Industry Overviews

    Key Cannabis Sector Updates: Analyst Ratings and Earnings

    Last week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%.

    By Mohit Oberoi, CFA
  • uploads///INSY
    Company & Industry Overviews

    How Is INSYS Therapeutics Financially Positioned in January?

    In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.

    By Daniel Collins
  • uploads///GW revenue
    Company & Industry Overviews

    A Look into GW Pharmaceuticals’ Revenue Trends

    In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.

    By Daniel Collins
  • uploads///Chart XXII
    Company & Industry Overviews

    Analyzing 22nd Century Group’s Year-to-Date Performance

    Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.

    By Mike Benson
  • uploads///Chart Insys
    Company & Industry Overviews

    A Closer Look at Insys Therapeutics’ Performance Year-to-Date

    Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

    By Mike Benson
  • uploads///seedling _
    Company & Industry Overviews

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

    By Mike Benson
  • uploads///marijuana _
    Healthcare

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.

    By Mike Benson
  • uploads///Cara SGA
    Company & Industry Overviews

    Comparing Cara Therapeutics’ Financial Performance

    Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]

    By Kenneth Smith
  • uploads///oral CR
    Company & Industry Overviews

    Cara Therapeutics’ Collaboration Agreements

    Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]

    By Kenneth Smith
  • uploads///Cara Analysts reco
    Company & Industry Overviews

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.

    By Kenneth Smith
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.